Johnson & Johnson



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Johnson & Johnson rose $1.64 (1.9%) to $86.99 on average volume. Throughout the day, 11,913,808 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10,100,300 shares. The stock ranged in a price between $85.94-$87.32 after having opened the day at $85.95 as compared to the previous trading day's close of $85.35. Other companies within the Drugs industry that increased today were:

Raptor Pharmaceutical



), up 26.6%,

Oramed Pharmaceuticals



), up 9.3%,

ARCA biopharma



), up 8.3% and

Nektar Therapeutics



), up 8.2%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $237.7 billion and is part of the health care sector. The company has a P/E ratio of 23.1, above the S&P 500 P/E ratio of 17.7. Shares are up 21.8% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

NewLink Genetics



), down 11.6%,

Prima Biomed



), down 9.7%,




), down 9.4% and

PTC Therapeutics



), down 8.5%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.